丹参酮ⅡA联合尼可地尔对冠心病左主干病变患者的临床疗效分析

Clinical Efficacy Analysis of TanshinoneⅡA Combined with Nicorandil in Patients with Left Main Coronary Artery Disease

目的:观察丹参酮ⅡA联合尼可地尔对冠心病左主干病变患者的临床疗效。方法:选取2016年10月-2019年7月在湖南省脑科医院心内科住院治疗的冠心病患者60例为研究对象。通过随机数字表法将其分为试验组和对照组,每组30例。对照组予以尼可地尔治疗,试验组予以丹参酮ⅡA磺酸钠注射液联合尼可地尔治疗。治疗2周后比较两组胸痛症状改善情况、心电图总有效情况及超敏C反应蛋白(hs-CRP)水平,并比较治疗后3个月两组左室射血分数(LVEF)和6 min步行试验距离。结果:治疗2周后,两组胸痛发作频率、持续时间均治疗前有明显改善,且试验组发作频率低于对照组,持续时间短于对照组,差异均有统计学意义(P<0.05)。治疗后,试验组心电图总有效率为86.67%,高于对照组的63.33%,差异有统计学意义(P<0.05)。治疗后,两组hs-CRP水平均较治疗前下降,且试验组hs-CRP水平低于对照组,差异均有统计学意义(P<0.05)。治疗后3个月,两组LVEF、6 min步行试验距离均较治疗前明显改善,且试验组LVEF较对照组改善更显著,差异均有统计学意义(P<0.05)。结论:对左主干病变的冠心病患者采用丹参酮ⅡA磺酸钠注射液联合尼可地尔治疗,可有效缓解症状,进一步提高临床效果,显著改善患者心脏功能的远期预后。

Objective:To observe the clinical efficacy of TanshinoneⅡA combined with Nicorandil in the treatment of left main coronary artery disease.Method:A total 60 patients with coronary heart disease who were hospitalized in the Department of Cardiology of Hunan Brain Hospital from October 2016 to July 2019 were selected as the research objects.They were divided into experimental group and control group by random number table method,30 cases in each group.The control group was treated with Nicorandil,the experimental group was treated with TanshinoneⅡA Sodium Sulfonate Injection combined with Nicorandil.After 2 weeks of treatment,the improvement of chest pain symptoms,the total effective rate of electrocardiogram and the level of high sensitive C-reactive protein(hs-CRP)were compared between the two groups.The left ventricular ejection fraction(LVEF)and the 6-minute walking test distance were compared between the two groups 3 months after treatment.Result:After 2 weeks of treatment,the frequency and duration of chest pain in the two groups were significantly improved before treatment,the attack frequency of the experimental group was lower than that of the control group,and the duration was shorter than that of the control group,the differences were statistically significant(P<0.05).After treatment,the total effective rate of ECG in the experimental group was 86.67%,which was higher than 63.33%in the control group,the difference was statistically significant(P<0.05).After treatment,the level of hs-CRP in the two groups decreased compared with those of before treatment,and the level of hs-CRP in the experimental group was lower than that in the control group,the differences were statistically significant(P<0.05).3 months after treatment,LVEF and 6-min walking distance of the two groups were significantly improved compared with those of before treatment,and the LVEF of the experimental group was more significantly improved than that of the control group,the differences were statistically significant(P<0.05).Conclusion:TanshinoneⅡA Sodium Sulfonate Injection combined with Nicorandil can effectively relieve symptoms,further improve clinical effect,and significantly improve the long-term prognosis of patients with left main coronary artery disease.